G Sanna

Summary

Affiliation: European Institute of Oncology
Country: Italy

Publications

  1. ncbi request reprint Brain metastases in patients with advanced breast cancer
    G Sanna
    Department of Oncology, European Institute of Oncology, Milan, Italy
    Anticancer Res 27:2865-9. 2007
  2. ncbi request reprint Breast cancer in Hodgkin's disease and non-Hodgkin's lymphoma survivors
    G Sanna
    European Institute of Oncology, Medical Oncology, University of Milan Bicocca, Milan, Italy
    Ann Oncol 18:288-92. 2007
  3. ncbi request reprint Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancer
    G Sanna
    Department of Medicine, Unit for Medical Care, European Institute of Oncology, Milan, Italy
    Ann Oncol 17:1512-6. 2006
  4. ncbi request reprint Optimizing clinical care of patients with metastatic breast cancer: a new oral vinorelbine plus trastuzumab combination
    C Catania
    Division of Medical Oncology, Unit for Medical Care, Department of Medicine, European Institute of Oncology, Milan, Italy
    Ann Oncol 18:1969-75. 2007
  5. ncbi request reprint Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects
    M Colleoni
    Division of Medical Oncology, University of Milan School of Medicine, European Institute of Oncology, Milan, Italy
    Ann Oncol 17:232-8. 2006
  6. ncbi request reprint Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer
    F Nole
    European Institute of Oncology, Milan, Italy
    Ann Oncol 17:322-9. 2006
  7. ncbi request reprint Response of bilateral choroidal metastases of breast cancer to therapy with trastuzumab
    E Munzone
    Department of Medicine, Division of Medical Oncology, Day Hospital Unit, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Breast 14:380-3. 2005
  8. ncbi request reprint Are all high-grade breast cancers with no steroid receptor hormone expression alike? The special case of the medullary phenotype
    L Orlando
    Division of Medical Oncology, Department of Medicine, Division of Pathology and Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy
    Ann Oncol 16:1094-9. 2005
  9. ncbi request reprint Patients with advanced stage breast carcinoma immunoreactive to biotinylated Herceptin are most likely to benefit from trastuzumab-based therapy: an hypothesis-generating study
    A Sapino
    Dipartimento di Scienze Biomediche e Oncologia Umana, Universita di Torino, Torino, Italy
    Ann Oncol 18:1963-8. 2007
  10. ncbi request reprint The role of surgery in jaw bone necrosis associated with long-term use of bisphosphonates
    G Sanna
    Acta Oncol 47:476-8. 2008

Detail Information

Publications15

  1. ncbi request reprint Brain metastases in patients with advanced breast cancer
    G Sanna
    Department of Oncology, European Institute of Oncology, Milan, Italy
    Anticancer Res 27:2865-9. 2007
    ..The incidence of brain metastases (BM) is apparently rising in patients with advanced breast cancer (ABC). We performed a case control study to define current features of breast cancer related to central nervous system (CNS) metastases...
  2. ncbi request reprint Breast cancer in Hodgkin's disease and non-Hodgkin's lymphoma survivors
    G Sanna
    European Institute of Oncology, Medical Oncology, University of Milan Bicocca, Milan, Italy
    Ann Oncol 18:288-92. 2007
    ..The primary end points were disease-free survival (DFS) and overall survival (OS)...
  3. ncbi request reprint Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancer
    G Sanna
    Department of Medicine, Unit for Medical Care, European Institute of Oncology, Milan, Italy
    Ann Oncol 17:1512-6. 2006
    ..In recent years, several cases of mandibular necrosis associated with long-term use of bisphosphonates have been reported. The estimated incidence varies from 1% to 4.6%...
  4. ncbi request reprint Optimizing clinical care of patients with metastatic breast cancer: a new oral vinorelbine plus trastuzumab combination
    C Catania
    Division of Medical Oncology, Unit for Medical Care, Department of Medicine, European Institute of Oncology, Milan, Italy
    Ann Oncol 18:1969-75. 2007
    ..In order to further improve quality of life of patients undergoing treatment for ABC, a new regimen using oral vinorelbine (oVNR) (d1 + d3) plus q3wks T was tested (ToVNR)...
  5. ncbi request reprint Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects
    M Colleoni
    Division of Medical Oncology, University of Milan School of Medicine, European Institute of Oncology, Milan, Italy
    Ann Oncol 17:232-8. 2006
    ..We previously demonstrated efficacy and impact on serum vascular endothelial growth factor (VEGF) for metronomic cyclophosphamide (C) and methotrexate (M) in patients with breast cancer. New metronomic schedules were investigated...
  6. ncbi request reprint Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer
    F Nole
    European Institute of Oncology, Milan, Italy
    Ann Oncol 17:322-9. 2006
    ....
  7. ncbi request reprint Response of bilateral choroidal metastases of breast cancer to therapy with trastuzumab
    E Munzone
    Department of Medicine, Division of Medical Oncology, Day Hospital Unit, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Breast 14:380-3. 2005
    ..The susceptibility of ocular metastases to this approach seems different to that of other sanctuary disease sites...
  8. ncbi request reprint Are all high-grade breast cancers with no steroid receptor hormone expression alike? The special case of the medullary phenotype
    L Orlando
    Division of Medical Oncology, Department of Medicine, Division of Pathology and Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy
    Ann Oncol 16:1094-9. 2005
    ..We retrospectively evaluated the clinical relevance of selected immunohistochemical features of tumors in three cohorts of patients with typical medullary (MC), 'atypical' medullary (AMC) or ductal (DC) breast carcinoma...
  9. ncbi request reprint Patients with advanced stage breast carcinoma immunoreactive to biotinylated Herceptin are most likely to benefit from trastuzumab-based therapy: an hypothesis-generating study
    A Sapino
    Dipartimento di Scienze Biomediche e Oncologia Umana, Universita di Torino, Torino, Italy
    Ann Oncol 18:1963-8. 2007
    ..We previously showed that BiotHER immunoreactivity is highly correlated with HER2 amplification and indicated that it could be associated with better clinical outcome in advanced breast cancer patients receiving trastuzumab...
  10. ncbi request reprint The role of surgery in jaw bone necrosis associated with long-term use of bisphosphonates
    G Sanna
    Acta Oncol 47:476-8. 2008
  11. ncbi request reprint Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the "Euro-Lupus Project"
    Ricard Cervera
    Department of Autoimmune Diseases, Servei de Malalties Autoimmunes, Hospital Clinic, Villarroel 170, 08036 Barcelona, Catalonia, Spain
    Autoimmun Rev 5:180-6. 2006
    ..The "Euro-Lupus Cohort" provides an updated information on the SLE morbidity and mortality characteristics in the present decade as well as defines several clinical and immunological prognostic factors...
  12. ncbi request reprint Jaw avascular bone necrosis associated with long-term use of biphosphonates
    G Sanna
    Ann Oncol 16:1207-8. 2005
  13. ncbi request reprint Headache and systemic lupus erythematosus
    M J Cuadrado
    Lupus Research Unit, The Rayne Institute, St Thomas Hospital, London, UK
    Lupus 12:943-6. 2003
    ..Other concomitant causes such as infection or hypertension should be excluded before assuming that headache is a feature of SLE activity. Therapeutic approach of headache SLE-related remains empirical and based on clinical experience...
  14. ncbi request reprint Central nervous system lupus: a clinical approach to therapy
    G Sanna
    Department of Rheumatology, Homerton University Hospital, London E9 6SR, UK
    Lupus 12:935-42. 2003
    ..Anticoagulation is warranted in patients with thrombotic disease, particularly in those with the antiphospholipid syndrome (APS). This article reviews the clinical approach to therapy in patients with CNS lupus...
  15. ncbi request reprint Lessons from the "Euro-Lupus Cohort"
    Ricard Cervera
    Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Catalonia, Spain
    Ann Med Interne (Paris) 153:530-6. 2002
    ..The "Euro-Lupus Cohort" provides an updated information on the SLE morbidity and mortality characteristics in the present decade as well as defines several clinical and immunological prognostic factors...